Pancreatic Cancer Research

ResearcherUniversité de BordeauxActive in the last 2 years

L. Chiche

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7580-2476; OpenAlex author ID A5057889505. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 3 papers · 2018: 1 paper · 2019: 4 papers · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 17

  1. International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot. Co-author DOI 10.1016/j.suronc.2026.102580↗
  2. Influence of pancreatic fistula on survival after upfront pancreatoduodenectomy for pancreatic ductal adenocarcinoma: multicentre retrospective study. Co-author DOI 10.1093/bjsopen/zrae125↗
  3. Response to the comment of V. Vashney and A. Swami for "pre-operative embolization of a replaced right hepatic artery before pancreaticoduodenectomy for pancre… Co-author DOI 10.1016/j.hpb.2021.11.002↗
  4. KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence. Co-author DOI 10.1038/s41598-022-07004-x↗
  5. Does pre-operative embolization of a replaced right hepatic artery before pancreaticoduodenectomy for pancreatic adenocarcinoma affect postoperative morbidity … Co-author DOI 10.1016/j.hpb.2021.04.003↗
  6. Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery. Co-author DOI 10.1080/0284186x.2021.1944662↗
  7. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre. Co-author DOI 10.1016/j.dld.2019.03.004↗
  8. CD63-GPC1-Positive Exosomes Coupled with CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.tranon.2019.07.009↗
  9. Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers11060852↗
  10. High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocarcinoma Patients Eligible for Up-Front Su… Last author DOI 10.3390/cancers11111656↗
  11. Severe postoperative complications decrease overall and disease free survival in pancreatic ductal adenocarcinoma after pancreaticoduodenectomy. Co-author DOI 10.1016/j.ejso.2018.03.024↗
  12. Resectable pancreatic adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting pathology and patient outcomes. Co-author DOI 10.1016/j.ejrad.2017.02.033↗
  13. Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease. Co-author DOI 10.1016/j.ejrad.2017.06.028↗
  14. Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment?… Co-author DOI 10.1016/j.ejso.2017.06.011↗
  15. Severe Jaundice Increases Early Severe Morbidity and Decreases Long-Term Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.jamcollsurg.2015.03.058↗
  16. Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the Associati… Co-author DOI 10.1245/s10434-014-4304-3↗
  17. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Co-author DOI 10.1148/radiol.14132914↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christophe Laurent · 10 shared papers, 2014–2024 · strength 1.14
  2. Étienne Buscail · 6 shared papers, 2019–2022 · strength 0.60
  3. Sandrine Dabernat · 5 shared papers, 2019–2022 · strength 0.49
  4. Olivıer Turrini · 5 shared papers, 2015–2024 · strength 0.49
  5. António Sá Cunha · 6 shared papers, 2014–2024 · strength 0.46
  6. V. Vendrely · 5 shared papers, 2014–2021 · strength 0.38
  7. Jean‐Robert Delpéro · 5 shared papers, 2015–2021 · strength 0.36
  8. Arthur Marichez · 2 shared papers, 2021–2022 · strength 0.35
  9. Alain Sauvanet · 4 shared papers, 2015–2024 · strength 0.34
  10. Jonathan Garnier · 2 shared papers, 2021–2024 · strength 0.30
  11. Fabrice Muscari · 2 shared papers, 2019–2024 · strength 0.28
  12. Charlotte Maulat · 2 shared papers, 2019–2024 · strength 0.28
  13. Christophe Cassinotto · 4 shared papers, 2014–2019 · strength 0.26
  14. François Paye · 4 shared papers, 2015–2018 · strength 0.23
  15. Jean‐Frédéric Blanc · 3 shared papers, 2014–2021 · strength 0.23
  16. Claudia Pouypoudat · 2 shared papers, 2019–2021 · strength 0.19
  17. Fanny Castanet · 1 shared paper, 2024 · strength 0.18
  18. Catherine Alix‐Panabières · 2 shared papers, 2019 · strength 0.18
  19. Samuel Amintas · 1 shared paper, 2022 · strength 0.16
  20. Philippe Bachellier · 3 shared papers, 2015–2017 · strength 0.15
  21. B. Gallix · 2 shared papers, 2017 · strength 0.14
  22. George Zogopoulos · 2 shared papers, 2017 · strength 0.14
  23. Ugo Marchèse · 1 shared paper, 2021 · strength 0.12
  24. Mario Terlizzi · 1 shared paper, 2021 · strength 0.11
  25. Mustapha Adham · 2 shared papers, 2015–2017 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.